Trial · NCT03326063
Outcomes15
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Provocative Dose 2 (PD2) During Aspirin Challenge | 6 weeks from screening visit ( at visit 2) | mg | MEAN | |
| SECONDARY | Percentage Change From Baseline of FEV1 During Aspirin Challenge (Bronchoconstriction) | At Visit 2. The change in FEV1 from the morning baseline to the aspirin-induced lowest value in FEV1 during reaction to aspirin challenge later that same day. | percentage change from baseline | MEAN | |
| SECONDARY | Aspirin-induced Leukotriene E4 (LTE4) Levels | Visit 2. The change in LTE4 levels from the morning baseline to the aspirin-induced highest value in LTE4 during reaction to aspirin challenge that same day. | ng/mg creatinine | MEAN | |
| SECONDARY | Change in Chronic Disease Control by Measurement of Lung Function Through FEV1 | 1 month (between Visit 1 and Visit 2) | percent change from baseline | MEAN | |
| SECONDARY | Change in Chronic Disease by Measurement of Asthma Control Through Asthma Control Questionnaire (ACQ) Score | 1 month (between Visit 1 and Visit 2) | scores on a scale | MEAN | |
| SECONDARY | Clinical Improvement of Chronic Disease - Sino-Nasal Outcome Test (SNOT-22) Score | 1 month (between Visit 1 and Visit 2) | scores on a scale | MEAN | |
| SECONDARY | Fractional Exhaled Nitric Oxide (FeNO) | 1 month (between Visit 1 and Visit 2) | parts per billion | MEAN | |
| OTHER_PRE_SPECIFIED | Percent Change in Urinary Eicosanoid (TXB2 and LTE4) Levels | 1 month (between Visit 1 and Visit 2) and 6 weeks from screening visit ( at visit 2) | |||
| OTHER_PRE_SPECIFIED | Nasal Eicosanoid Changes | 1 month (between Visit 1 and Visit 2) and 6 weeks from screening visit ( at visit 2) | |||
| OTHER_PRE_SPECIFIED | Plasma/Serum Tryptase Changes | 1 month (between Visit 1 and Visit 2) and 6 weeks from screening visit ( at visit 2) | |||
| OTHER_PRE_SPECIFIED | Nasal Tryptase Changes | 1 month (between Visit 1 and Visit 2) and 6 weeks from screening visit ( at visit 2) | |||
| OTHER_PRE_SPECIFIED | Platelet Activation - Numbers of Activated Platelets | 1 month (between Visit 1 and Visit 2) and during aspirin challenge visit | |||
| OTHER_PRE_SPECIFIED | Platelet Activation - Percentages of Activated Platelets | 1 month (between Visit 1 and Visit 2) and 6 weeks from screening visit ( at visit 2) | |||
| OTHER_PRE_SPECIFIED | Platelet Activation - Numbers of Platelet-leukocyte Aggregates | 1 month (between Visit 1 and Visit 2) and 6 weeks from screening visit ( at visit 2) | |||
| OTHER_PRE_SPECIFIED | Platelet Activation - Percentages of Platelet-leukocyte Aggregates | 1 month (between Visit 1 and Visit 2) and 6 weeks from screening visit ( at visit 2) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03326063/outcomes